Epidemiological and clinical features of SARS-CoV-2 infection in children during the outbreak of Omicron variant in Shanghai, March 7-31, 2022Article Published on 2022-11-012022-11-16 Journal: Influenza and Other Respiratory Viruses [Category] SARS, 변종, [키워드] 95% confidence interval Asymptomatic calculated children clinical Clinical characteristics clinical feature collected Community confirmed cases cough COVID-19 COVID-19 case COVID-19 vaccination COVID-19 vaccine dissemination dose early stage eligible epidemiological febrile disease Fever hospital Infection interquartile range leukopenia Local median median interval offer omicron Omicron SARS-CoV-2 variant outbreak pediatric Pediatric case reduced Relative risk risk RRs SARS-CoV-2 SARS-COV-2 infection Seven Shanghai symptomatic case symptomatic infection Transmission model vaccination Vaccines variant [DOI] 10.1111/irv.13044 PMC 바로가기
MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literatureArticle Published on 2022-10-012022-11-15 Journal: Journal of Neurology [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] acute respiratory syndrome Adults affected analysed antibody AstraZeneca attack available data AZD1222 blindness BNT162b2 booster vaccination Brain Brainstem Brainstem encephalitis Case report cerebrospinal fluid ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1-S CNS complete recovery coronavirus Coronavirus disease 2019 Coronavirus disease 2019 (COVID-2019) COVID-19 CSF detectable disease dysfunction Encephalitis epidemiological Escalation exceeded female first dose functional glycoprotein IgG1 immunization Immunoglobulin Immunotherapy laboratory feature Longitudinally extensive transverse myelitis (LETM) majority male median median age median interval MOG MOG antibodies (MOG-IgG) mRNA vaccine mRNA-1273 much lower Myelin Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) Myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis (MOG-EM) Myelitis Neuromyelitis Optica Neuromyelitis optica spectrum disorders occur occurred Optic Optic neuritis Oxford paraplegia Patient patients patients with SARS-CoV-2 Pfizer phenotype plasma Postinfectious Postvaccinal predominant radiological remained required residual symptom SARS-CoV2 serum Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) severity steroid treatment therapy Treatment Treatment outcome vaccination Vaccine WCC white cell [DOI] 10.1007/s00415-022-11194-9 PMC 바로가기
Comparison of acute respiratory distress syndrome in patients with COVID-19 and influenza A (H7N9) virus infectionResearch article Published on 2022-09-012022-10-05 Journal: International Journal of Infectious Diseases [Category] 진단, 치료기술, [키워드] acute respiratory distress acute respiratory distress syndrome analyzed ARDS assessment cause clinical clinical feature coagulation disorder coagulation dysfunction COVID-19 death develop died disease disease course Disseminated intravascular coagulation failure H7N9 Hypoxemia illness onset infections Inflammatory Inflammatory response influenza A Liver injury median interval multiple organ dysfunction objective paO2/fiO2 Patient patients with COVID-19 proportion Result SARS-CoV-2 Septic shock severe ARDS susceptible syndrome virus virus infection [DOI] 10.1016/j.ijid.2022.06.053 [Article Type] Research article
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trialChAdOx1 nCoV-19 또는 BNT162b2 2회 접종 및 BNT162b2(COV-BOOST) 3차 접종 후 4차 접종으로 제공된 BNT162b2 및 mRNA-1273 COVID-19 백신의 안전성, 면역원성 및 반응성: 다기관, 맹검, 단계 2, 무작위 시험Clinical Trial Published on 2022-08-012022-09-11 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] 1:1 95% CI adverse event All participants analysed anti-spike protein IgG assigned blinded block size BNT162b2 boost booster Booster vaccine cellular Cellular and humoral immunity Cellular immune response ChAdOx1 nCoV-19 computer-generated Concentration Controlled trial country COV-BOOST COVID-19 COVID-19 vaccine COVID-19 vaccines dose doses Effectiveness ELISA ELISPOT Endpoint enrolled fatigue female Fold change Fold changes force geometric geometric mean groups Humoral immunity immunogenicity Intramuscular injection IQR ISRCTN Laboratory Local male median age median interval Moderna modified intention-to-treat mRNA mRNA-1273 mRNA-1273 booster mRNA-1273 COVID-19 vaccine multicentre of BNT162b2 outcome participant peak per-protocol population Pfizer-BioNTech Phase 2 random randomisation list randomised controlled trial Randomised trial Randomly reactogenicity receive Registered reported representing response Safety SARS-CoV-2 screened Serious Adverse Event seronegative participant seronegative participants serostatus Seven significant increase statistician T-cell Response T-cell responses Task Force the vaccine the vaccines titre treatment allocation Trial upper arm Vaccine variant were assessed wild-type [DOI] 10.1016/S1473-3099(22)00271-7 PMC 바로가기 [Article Type] Clinical Trial
Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response회복기 혈장의 항체는 내인성 항체 반응이 있거나 없는 개인에서 SARS-CoV-2 제거를 촉진합니다Clinical Trial Published on 2022-06-152022-09-11 Journal: The Journal of Clinical Investigation [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, [키워드] 95% CI absence Adaptive immunity adjusted hazard ratio adverse events affected antibody Antibody Response clearance Clinical research Comorbidity Comprehensive conducted convalescent plasma Convalescent plasma therapy Corona COVID-19 Critical demonstrated disease status Efficacy evidenced faster hazard ratio hospitalized COVID-19 patient human infection human infections Immunotherapy individual Innovation Intervention IQR Kaplan-Meier analysis laboratory parameter median interval Mortality neutralization Neutralizing neutralizing antibody onset of symptom parameter Phase I plasma plasma therapy pool principle priority Program promote recipient recipients Red respond Safe SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 clearance SARS-CoV-2 vaccines serological significantly survival therapeutic Therapeutics therapy transfusion-related adverse event transfusion-related adverse events Trial university University of Zurich Viral viral clearance Viral load Viremia Virological virus clearance [DOI] 10.1172/JCI158190 PMC 바로가기 [Article Type] Clinical Trial
Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 VaccineBNT162b2 코비드-19 백신 3차 접종의 안전성 및 효능Clinical Trial Published on 2022-05-192022-09-25 Journal: The New England Journal of Medicine [Category] COVID19(2023년), SARS, 임상, 진단, 치료법, [키워드] 95% confidence interval active immunization acute respiratory syndrome Administered age assigned BNT162b2 BNT162b2 vaccine booster coronavirus coronavirus disease Critical dose Efficacy evaluated event Evidence Follow-up Infection injected median median interval myocarditis of BNT162b2 Older pandemic participant Pfizer-BioNTech phase 3 trial Placebo placebo-controlled provided Randomized reported Safety SARS-CoV-2 SARS-COV-2 infection second dose systemic reactogenicity the median the placebo group the vaccine Vaccine [DOI] 10.1056/NEJMoa2200674 PMC 바로가기 [Article Type] Clinical Trial
A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines불활성화 백신 2회 투여 후 성인에서 AZD1222의 저용량 대 표준 용량의 추가 용량에 대한 무작위 임상 시험Randomized Controlled Trial Published on 2022-04-202022-09-11 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] 95% CI Adults anti-S anti-SARS-CoV-2 IgG anti-SARS-CoV-2 IgG. Anti-spike antibody Antibody titer ARMS AstraZeneca AZD1222 baseline booster booster dose ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine completion conducted CoronaVac CoronaVac vaccine delta variant dose double-blinded enrolled evaluate Fever geometric geometric mean geometric mean ratio Geometric means GMR GMRs healthy IgG immunogenicity inactivated Inactivated vaccine Infection IQR low dose low-dose median age median interval myalgia neutralization test neutralizing antibody Neutralizing antibody titer participant Prevent Randomized randomized clinical trial randomized, controlled trial RBD IgG reactogenicity receive recipient S-RBD SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine significantly lower Standard dose surrogate surrogate virus neutralization test sVNT systemic reactogenicity the SARS-CoV-2 variant Viral Viral particles virus neutralization test wild type [DOI] 10.1016/j.vaccine.2022.03.036 PMC 바로가기 [Article Type] Randomized Controlled Trial
Liver or Kidney Transplantation After SARS-CoV-2 Infection: Prevalence, Short-term Outcome, and Kinetics of Serum IgG AntibodiesSARS-CoV-2 감염 후 간 또는 신장 이식: 혈청 IgG 항체의 유병률, 단기 결과 및 동역학Article Published on 2022-04-012022-09-11 Journal: Transplantation [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] Absolute level absolute levels acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 analyzed anti-S IgG antibody Chain Reaction Clinical sign Clinical signs Cohort Coronavirus-2 Course declined detectable died Follow-up IgG IgG antibodies IgG antibody Immunoglobulin Immunoglobulin G individuals Infection kidney Kinetics liver median median interval Nasopharyngeal swab one patient organ transplantation outcome Patient patients paucity of data polymerase chain polymerase chain reaction positive positively correlated Prevalence remained respiratory SARS-CoV-2 SARS-COV-2 infection selected seroconverted patient Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus significantly lower solid organ solid organ transplantation symptom resolution transplantation Viral viral shedding [DOI] 10.1097/TP.0000000000003955 PMC 바로가기 [Article Type] Article
Initial Experience With SARS-CoV-2-Neutralizing Monoclonal Antibodies in Kidney or Combined Kidney-Pancreas Transplant Recipients신장에서 SARS-CoV-2-중화 단일클론항체 또는 신장-췌장 결합 이식 환자에 대한 초기 경험Article Published on 2022-03-312022-09-11 Journal: Transplant International [Category] MERS, SARS, 변종, 진단, [키워드] Administered analyzed antibodies antiviral drugs appear bamlanivimab clinical outcomes co-primary endpoint co-primary endpoints Combined Contact coronavirus COVID-19 death drug effective Emergency use authorization EUA experience Hospitalization Hospitalized hospitalized patient identify Imdevimab Immunocompromised Immunosuppression IQR kidney Kidney transplantation lymphoma mAb median interval monoclonal antibodies monoclonal antibody Mortality negativity Organ transplant overall mortality Patient PCR negativity positive receive recipient recipients renal function respiratory Respiratory Coronavirus SARS-CoV-2 SARS-CoV-2 RT-PCR shown single dose single doses Spike protein Transplant treated Treatment U.S. FDA variant Viral viral spike viral spike protein virus-specific antibodies [DOI] 10.3389/ti.2022.10109 PMC 바로가기 [Article Type] Article
Absence of SARS-CoV-2 Spike glycoprotein expression in placentas from individuals after mRNA SARS-CoV-2 vaccination Research Published on 2022-03-312022-10-05 Journal: Modern pathology : an official journal of the Unit [Category] SARS, 진단, [키워드] absence accumulate acute respiratory syndrome collected Concentration coronavirus current determine dose effort Evidence expression General population gestation global pandemic glycoprotein group Hesitancy immune cells immunohistochemistry include individual injection interval median interval MOST mRNA mRNA vaccine negative control negative controls observation occur paraffin-embedded Patient Placenta placental tissue Population positive positive control Pregnancy pregnant Protein protein translation provide public health receiving SARS-CoV-2 SARS-CoV-2 RNA SARS-CoV-2 vaccination SARS-CoV-2 vaccine spike spontaneous abortion the SARS-CoV-2 the study group translation vaccination vaccine dose was used [DOI] 10.1038/s41379-022-01061-3 [Article Type] Research